Lygidakis N J, Berberabe A E, Spentzouris N, Dedemadi G, Kalligas T, Loukas G, Sotiropoulou B
Athens Medical Center (P. Faliron), Department of Surgical Oncology, Greece.
Hepatogastroenterology. 1998 Nov-Dec;45(24):2248-51.
BACKGROUND/AIMS: A retrospective report of our experience with adjuvant targeted locoregional immunochemotherapy using new drugs in 29 Stage IV colorectal cancer patients with unresectable metastatic liver disease from September 1997 to December 1998.
After pre-operative screening, all patients were subjected to laparotomy for insertion of transhepatic and transplenic arterial catheters, both implanted subcutaneously in the right upper abdominal quadrant. A bolus transhepatic arterial chemotherapy using Eloxatine 150 mg/m2 and Campton 140 mg/m2, suspended in a 5:1 lipiodol-urografin emulsion, was given 15 days post-operatively, followed the day after by 5 daily transplenic artery and then 5 daily transhepatic arterial injections of IL-2 in a 5:1 lipiodol-urografin mixture. This treatment schema was repeated at 2-month intervals.
Treatment response was recorded: CR=24.2%, PR=55.2%, SD=10.3%, and PD=10.3%. Seventy-nine percent responded favorably with 7 patients (24.2%) showing marked tumor bulk reductions. There were no treatment-related morbidities or mortalities.
All 29 patients are alive with a median survival of 11 months as of this writing. Eighty percent report a significant improvement in quality of life. Targeted locoregional immunochemotherapy using the above drugs is a promising option for patients with far-advanced metastatic liver disease.
背景/目的：回顾性报告1997年9月至1998年12月期间，我们使用新药对29例伴有不可切除转移性肝病的IV期结直肠癌患者进行辅助性局部区域免疫化疗的经验。
术前筛查后，所有患者均接受剖腹手术，经肝和经脾插入动脉导管，二者均皮下植入右上腹象限。术后15天经肝动脉推注化疗，使用150mg/m²奥沙利铂和140mg/m²喜树碱，悬浮于5:1的碘油-泛影葡胺乳剂中，术后第16天开始，连续5天经脾动脉、然后连续5天经肝动脉注射IL-2，均溶于5:1的碘油-泛影葡胺混合液中。该治疗方案每2个月重复一次。
记录治疗反应：完全缓解（CR）=24.2%，部分缓解（PR）=55.2%，疾病稳定（SD）=10.3%，疾病进展（PD）=10.3%。79%的患者反应良好，7例（24.2%）患者肿瘤体积显著缩小。无治疗相关的发病率或死亡率。
截至撰写本文时，所有29例患者均存活，中位生存期为11个月。80%的患者报告生活质量有显著改善。使用上述药物进行局部区域免疫化疗对晚期转移性肝病患者是一种有前景的选择。
